0001104659-17-041909.txt : 20170628
0001104659-17-041909.hdr.sgml : 20170628
20170628060108
ACCESSION NUMBER: 0001104659-17-041909
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170623
FILED AS OF DATE: 20170628
DATE AS OF CHANGE: 20170628
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sender Gary
CENTRAL INDEX KEY: 0001659085
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17933657
MAIL ADDRESS:
STREET 1: C/O SYNERGY PHARMACEUTICALS INC.
STREET 2: 420 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10020
4
1
a4.xml
4
X0306
4
2017-06-23
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001659085
Sender Gary
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
Chief Financial Officer
Ordinary Shares
2017-06-23
5
J
0
E
2200
0
A
2200
D
Stock Option
2017-06-23
5
J
0
E
88800
0
A
2026-05-30
Ordinary Shares
88800
88800
D
Stock Option
2017-06-23
5
J
0
E
113000
0
A
2027-02-06
Ordinary Shares
113000
113000
D
Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
The exercise price is 6.50 Euro.
This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
The exercise price is 7.963 Euro.
This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.
/s/ Gary L. Sender
2017-06-27